Rocket Pharmaceuticals, Inc. (RCKT) News

Rocket Pharmaceuticals, Inc. (RCKT): $19.88

1.49 (+8.10%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RCKT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 381

in industry

Filter RCKT News Items

RCKT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RCKT News Highlights

  • For RCKT, its 30 day story count is now at 6.
  • Over the past 18 days, the trend for RCKT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about RCKT are RARE, PCRX and ALVR.

Latest RCKT News From Around the Web

Below are the latest news stories about ROCKET PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RCKT as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Welcome back, trader!

William White on InvestorPlace | November 28, 2022

Rocket Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference

CRANBURY, N.J., November 21, 2022--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that Gaurav Shah, M.D., Chief Executive Officer, will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022, at 3:30 p.m. ET.

Yahoo | November 21, 2022

A Look At The Fair Value Of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Does the November share price for Rocket Pharmaceuticals, Inc. ( NASDAQ:RCKT ) reflect what it's really worth? Today...

Yahoo | November 16, 2022

Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT) and AlloVir (ALVR)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rocket Pharmaceuticals (RCKT – Research Report) and AlloVir (ALVR – Research Report) with bullish sentiments. Rocket Pharmaceuticals (RCKT) Raymond James analyst Steven Seedhouse maintained a Buy rating on Rocket Pharmaceuticals today and set a price target of $33.00. The company's shares closed last Friday at $17.01. According to TipRanks.

Christine Brown on TipRanks | November 7, 2022

Analysts Are Bullish on These Healthcare Stocks: Pacira Pharmaceuticals (PCRX), Rocket Pharmaceuticals (RCKT)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Pacira Pharmaceuticals (PCRX – Research Report), Rocket Pharmaceuticals (RCKT – Research Report) and Kezar Life Sciences (KZR – Research Report) with bullish sentiments. Pacira Pharmaceuticals (PCRX) Wedbush analyst Liana Moussatos reiterated a Buy rating on Pacira Pharmaceuticals today and set a price target of $88.00. The company's shares closed last Thursday at $49.59, close to its 52-week low of $47.57. According to TipRanks.com, Moussatos is ranked 0 out of 5 stars with an average return of -24.9% and a 25.9% success rate.

Brian Anderson on TipRanks | November 4, 2022

Rocket Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

CRANBURY, N.J., November 03, 2022--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today reports financial results for the quarter ending September 30, 2022, and updates from the Company’s key pipeline developments, business operations and upcoming milestones.

Yahoo | November 3, 2022

Rocket Pharmaceuticals Announces Presentations Highlighting AAV and Lentiviral Gene Therapies at Upcoming Scientific Congresses

CRANBURY, N.J., November 03, 2022--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces upcoming data presentations at the 75th American Heart Association (AHA) Annual Meeting, taking place in Chicago, Illinois, and virtually, from Nov. 5-7, 2022, and the 64th American Society of Hematology (ASH) Annual Meeting, taki

Yahoo | November 3, 2022

Wall Street Analysts See an 184% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High?

The mean of analysts' price targets for Rocket Pharmaceuticals (RCKT) points to an 183.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | October 27, 2022

Alkermes, Allakos, and Other Stocks See Action From Activist Investors

Sarissa Capital disclosed a large stake in pharmaceutical firm Alkermes. New Enterprise Associates more than doubled its investment in clinical-stage drug firm Allakos.

Yahoo | October 14, 2022

Which Stocks are Insiders Buying?

TipRanks tracks corporate insiders' Informative Buys of shares of their own companies. These Buys could be indicative of positive developments within a company, so investors often find this information useful.

TipRanks Team on TipRanks | October 12, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6832 seconds.